Radiopharmaceutical company Viewpoint Molecular Targeting is set to merge with medical technology company Isoray (NYSE:ISR), subject to approval by the shareholders of both the companies. According to the definitive merger agreement, each issued and outstanding share of Viewpoint will be converted into the right to receive 3.3212 shares of Isoray. The Viewpoint stockholders will own 49% of the fully diluted outstanding capital stock of Isoray. The transaction will increase the size of Isoray's board to 5 with 2 directors to be designated by Viewpoint and 3 directors to be designated by Isoray. Isoray's Lori Woods will serve as the chairperson.